Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Maria L. Baeza"'
Autor:
A. Prieto, Pilar Tornero, T. Herrero, Maria L. Baeza, Alejandro La Rotta, Guadalupe Marco-Martín
Publikováno v:
Neurol Clin Pract
Purpose of reviewDiverse adverse events have been associated with administration of glatiramer acetate (GA), mainly local reactions at the injection site. Other, less frequent generalized reactions include isolated postinjection reactions and anaphyl
Autor:
F.J. Muñoz-Bellido, M. Castro, B. Sáenz de San Pedro, C. Díaz, E. Escudero, Maria L. Baeza, Anna Sala-Cunill, Teresa Caballero, A. Prieto-García, M.G. García, R. Núñez, T González-Quevedo, S. Varela, E. Laffond, Mar Guilarte, R. Lleonart, N. Prior
Publikováno v:
The journal of allergy and clinical immunology. In practice. 10(4)
[Background] Data on acquired angioedema due to C1-inhibitor deficiency (C1-INH-AAE) from 4 European countries (France, Italy, Germany, and Hungary) were recently published.
[Objective] To report data from a group of 50 patients with acquired C1
[Objective] To report data from a group of 50 patients with acquired C1
Autor:
Maria Pilar Gil, Allen P. Kaplan, Nuria Rodríguez-Garijo, Valeria Herrera-Lasso, Moises Labrador-Horrillo, Beatriz Veleiro, Julián Azofra, Carmen Diaz Donado, Maria L. Baeza, Marina Sabaté-Brescó, Pere Gaig, Anna Sala-Cunill, Mar Guilarte, Marta Ferrer
Publikováno v:
The journal of allergy and clinical immunology. In practice. 9(6)
Background Recurrent idiopathic histaminergic angioedema is currently classified as a subtype of angioedema, as well as a subtype of chronic spontaneous urticaria (CSU), based on the fact that both are mast cell-mediated and respond to the same treat
Autor:
Maria L. Baeza, Alberto Alvarez-Perea
Publikováno v:
Annals of Allergy, Asthma & Immunology
Autor:
P Cabrera Freitag, V Fuentes Aparicio, Maria L. Baeza, José Manuel Zubeldia, A Alvarez Perea, Sonsoles Infante, L. Zapatero
Publikováno v:
Journal of investigational allergologyclinical immunology. 29(6)
Publikováno v:
Clinical and Translational Allergy, Vol 7, Iss 1, Pp 1-10 (2017)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Clinical and Translational Allergy
Clinical and Translational Allergy, BioMed Central, 2017, 7 (1), pp.45. ⟨10.1186/s13601-017-0182-7⟩
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Clinical and Translational Allergy
Clinical and Translational Allergy, BioMed Central, 2017, 7 (1), pp.45. ⟨10.1186/s13601-017-0182-7⟩
International audience; Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction characterized by rapidly developing airway and/or circulation problems. It presents with very different combinations of symp
Autor:
José Manuel Zubeldia, Yoko Higaki, Guadalupe Marco-Martín, Maria L. Baeza, María Vázquez de la Torre, A Hernandez
Publikováno v:
International Archives of Allergy and Immunology. 173:204-212
Background: Anaphylaxis is a severe and potentially lethal allergic reaction whose incidence is increasing. Murine models can elucidate the underlying mechanisms and pave the way for appropriate therapeutic options. However, differences in strains an
Publikováno v:
Journal of Investigational Allergology and Clinical Immunology. 28:265-267
Autor:
Jacques Hébert, Hilary Longhurst, Jana Hanzlikova, Avner Reshef, Timothy J. Craig, William R. Lumry, Marco Cicardi, Sarah Mycroft, Ingo Pragst, Maria Dolores Hernandez, Emel Aygören-Pürsün, Constance H. Katelaris, Markus Magerl, Henrike Feuersenger, Paul K. Keith, Michael E. Manning, Petra Staubach-Renz, John Anderson, Ioana Crisan, Shmuel Kivity, Sergio Neri, Teresa Caballero, Iris Jacobs, William H. Yang, Inmaculada Martinez-Saguer, Bruce L. Zuraw, Gordon Sussman, Maria L. Baeza, Marc A. Riedl, Iftikar Hussain, Donald Levy, Clive Grattan, Konrad Bork, Joshua J. Jacobs, Dipti Pawaskar, Lawrence B. Schwartz, Henry Li, Sandra C. Christiansen, Jonathan A. Bernstein, Henriette Farkas
Background For the prevention of attacks of hereditary angioedema (HAE), the efficacy and safety of subcutaneous human C1-esterase inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) was established in the 16-week Clinical Study for Optimal Management of P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a49ffa76b8f8828cef7b385bc3eb0434
http://publikationen.ub.uni-frankfurt.de/files/49199/1-s2.0-S2213219819301631-main_n.pdf
http://publikationen.ub.uni-frankfurt.de/files/49199/1-s2.0-S2213219819301631-main_n.pdf
Publikováno v:
Journal of Allergy and Clinical Immunology. 147:AB136